Roche ($RHHBY) is reporting encouraging results from a mid-stage study of inclacumab, saying the data demonstrated a clear clinical benefit by reducing inflammation during angioplasty. Investigators tracked patients' response to the drug, comparing its effect on key biomarkers with a placebo. "It was exciting to see that a single administration of inclacumab would yield clinical benefit," Dr. Jean-Claude Tardif told Reuters at the American College of Cardiology scientific meeting in San Francisco. "This is huge potentially. A drug that blocks the inflammatory process on top of statins holds a lot of potential." Story